StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $1.37BP/E –Yield –

Intellia Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Intellia Therapeutics's price to sales ratio was 26.8× on Nov 11, 2026, against 18.1× a year earlier. Over the last 5 years it ranged from 12.5× to 328.1×, with a median of 61.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202626.8×+8.8
2025Dec 31, 202518.1×−22.9
2024Jan 31, 202441.0×−11.5
2023Dec 29, 202352.5×+0.5
2022Dec 30, 202252.0×−276.1
2021Dec 31, 2021328.1×+276.8
2020Dec 31, 202051.3×+33.4
2019Dec 31, 201917.9×−2.4
2018Dec 31, 201820.3×–

More Intellia Therapeutics figures

See a number that looks wrong?